investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

Validating Syk as a Target for AML Therapy

Kimberly Stegmaier

0 Collaborator(s)

Funding source

National Institutes of Health (NIH)

No posts

Related projects

Carol Prives

Properties and Regulation of p53 in Tumor Cells

Leukaemia

Pathology

Arnav Mehta

MicroRNA-125b physiologically and pathologically regulates myelopoiesis through I

Leukaemia

Vinay Pathak

Retroviral Replication and Interactions with Host Factors

Leukaemia

Pathology Hematology and hematologic malignancies

Mary Ellen Conley

Genetic Etiology of Agammaglobulinemia with Absent B Cells

Leukaemia

Effie W Petersdorf

Clinical Significance of MHC Haplotypes in HCT

Leukaemia

Michael R Green

Identification and Characterization of Genes that Suppress BCR-ABL+ Leukemia

Leukaemia

Pathology Hematology and hematologic malignancies

Catherine Ju-Ying Wu

Defining the Impact of Clonal Evolution on Chronic Lymphocytic Leukemia

Leukaemia

Pathology Hematology and hematologic malignancies

Wenwei Hu

The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer

Leukaemia

Amy Paguirigan

Connecting Single Cell Heterogeneity to Clinical Descriptors of Clonal Evolution in Acute Myeloid Leukemia

Leukaemia